Lassa virus infectious disease

Summary

Lassa virus infectious disease (MONDO:0044750) is a disease and 5 clinical trials. A subtype of Arenaviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lassa virus infectious disease
Mondo ID	MONDO:0044750
SNOMED CT	721779001
UMLS	C1617072
MedGen	923253
Is cancer (heuristic)	no

Also known as: infection caused by Lassa virus · Lassa virus infection

Disease family

This is a subtype of Arenaviridae infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Arenaviridae infectious disease › lassa virus infectious disease

Related subtypes (2): lymphocytic choriomeningitis, arenavirus hemorrhagic fever

Subtypes (1): Lassa fever

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04055454	PHASE1	COMPLETED	A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)
NCT04794218	PHASE1	UNKNOWN	A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath
NCT03655561	Not specified	ACTIVE_NOT_RECRUITING	Lassa Fever Clinical Course and Prognostic Factors in Nigeria
NCT02311387	Not specified	COMPLETED	Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali
NCT03783143	Not specified	COMPLETED	Prevalence and Incidence of Lassa Virus Infection in Southern Mali